Who is this relevant for?
- Hospitals managing supply risk
- Manufacturers evaluating market entry
- Distributors monitoring sourcing opportunities
Eugene Braunwald, widely regarded as the father of modern cardiology, died at age 96. The American College of Cardiology and the New York Times published obituaries honoring his legacy.
A new observational analysis in Heart Rhythm found that patients with obstructive hypertrophic cardiomyopathy taking mavacamten (Camzyos) face a disproportionately higher risk of developing atrial fibrillation. This safety signal matters for clinicians and payers alike.
In DOAC comparisons, apixaban (Eliquis) showed a better safety profile than rivaroxaban (Xarelto) or dabigatran (Pradaxa) for younger adults with nonvalvular atrial fibrillation, according to a JAMA Network Open study. Hospitals managing anticoagulation protocols should note this.
Several device approvals and updates emerged. Biotronik received FDA approval for its Acticor Sky and Rivacor Sky ICD and CRT-D systems. A software update from Boston Scientific aims to prevent its pacemakers from permanently entering safety mode—a problem dating back to 2024. Abbott's Ultreon 3.0 AI software gained FDA clearance for OCT imaging during complex PCI.
Other notable developments include a blood-filtering technique that slowed very early preeclampsia progression, published in Nature Medicine, and an updated multisociety document outlining training requirements in cardiac electrophysiology. Ultra-low temperature ablation showed early promise for scar-related ventricular tachycardia.
Manufacturers evaluating the US market should track these regulatory approvals. Distributors monitoring sourcing opportunities may find demand for the newly cleared devices and the updated software. Hospitals should update formularies and protocols accordingly.